TABLE 1.
Demographic and clinical characteristics of the validation cohort
| Variable | Control (n = 20) | RA (n = 20) | SLE (n = 18) |
|---|---|---|---|
| Age, mean ± SD (years) | 40.2 ± 2.9 | 45.7 ± 3.2 | 39.1± 3.3 |
| Males, n (%) | 5 (25) | 5 (25) | 3 (17) |
| BMI, mean ± SD (Kg/m2) | 20.9 ± 0.5 | 22.9 ± 0.7 | 22.1 ±0.5 |
| SLEDAI, n (%) | |||
| Inactive (0–11) | – | – | 10 (55) |
| Active (>11) | – | – | 8 (45) |
| Biochemistry, mean ± SD | |||
| IGG (g/L) | 17.8 ±4.8 | 13.5 ± 0.5 | 12.2 ± 1.1 |
| IGA (g/L) | 2.3 ± 0.2 | 3.2 ± 0.4 | 2.2 ± 0.4b |
| IGM (g/L) | 1.3 ± 0.1 | 1.1 ± 0.1 | 1.0 ±0.1a |
| C3 (g/L) | 1.2 ± 0.5 | 1.3 ± 0.6 | 1.0 ± 0.6b |
| C4 (g/L) | 0.3 ± 0.2 | 0.3 ± 0.1 | 0.3 ± 0.1 |
| C1q (mg/L) | 210.4 ± 8.4 | 221.6 ± 9.6 | 179.3 ± 8.3ab |
| CRP (mg/L) | 2.6 ± 1.4 | 16.4 ± 8.0a | 15.3 ± 8.7b |
| ASO (KIU/L) | 18.8 ± 26.7 | 45.2 ± 12.3a | 30.2 ± 5.9a |
| RF (IU/L) | 12.4 ±2.7 | 131.3 ±29.2a | 7.2 ± 0.7b |
| dsDNA | 21.5 ± 6.0 | 45.9 ±15.8a | 128.6 ± 39.0ab |
Abbreviations: ASO, antistreptolysin O; BMI, body mass index; C1q, complement Clq; C3, complement 3; C4, complement; CRP, C‐reactive protein; dsDNA, anti‐double stranded DNA; IGA, immunoglobulin A; IGG, immunoglobulin G; IGM, immunoglobulin M; RF, rheumatoid factors；
“‐”, not avialible; a, p < 0.05 compared with control; b, p < 0.05 compared with RA, by the Bonferroni method of multiple‐range testing.